Clorox Reports Fiscal 2025 Net Sales of $7.1 Billion; EPS Misses Guidance

Reuters
2025/08/09
Clorox Reports Fiscal 2025 Net Sales of $7.1 Billion; EPS Misses Guidance

The Clorox Company reported its financial results for fiscal year 2025, with net sales amounting to $7.1 billion, remaining essentially flat compared to the previous year. Despite macroeconomic uncertainties and changes in shopping behaviors leading to temporary category slowdowns, the company achieved organic sales and earnings growth. Clorox successfully expanded its overall market share and increased its gross margin during this period. A significant highlight for the company was a 190% increase in diluted net earnings per share $(EPS)$ compared to the prior fiscal year. This improvement was largely attributed to several factors, including losses associated with the divestiture of the Argentina business in the previous year, higher volume in the current period, and cost savings. Additionally, the benefits from cyberattack insurance recoveries contributed positively to the results, although these were partially offset by the loss related to another divestiture. The Clorox Company, with about 7,600 employees worldwide, continues to focus on building a stronger, more resilient business. The company operates in approximately 25 countries or territories and sells its products in around 100 markets globally, through various retail channels and e-commerce platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Clorox Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000021076-25-000039), on August 08, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10